Refine
Has Fulltext
- yes (4)
Is part of the Bibliography
- yes (4)
Document Type
- Journal article (4) (remove)
Language
- English (4)
Keywords
- neuroendocrine tumor (2)
- osteoporosis (2)
- vitamin D (2)
- LCNEC (1)
- MEN1 (1)
- adjuvant therapy (1)
- age (1)
- bone (1)
- bone metabolism (1)
- cortisol (1)
- epidemiology (1)
- genetic analysis (1)
- lymph nodes (1)
- miRNA (1)
- mineral bone density (1)
- mortality (1)
- neurofibromatosis type 1 (1)
- paraganglioma (1)
- pheochromocytoma (1)
- prognosis (1)
- prognostic marker (1)
- pulmonary cancer (1)
- serotonin (1)
- surgery (1)
- surveillance (1)
- survival (1)
- therapy (1)
- tumor (1)
Institute
No studies have carried out an extensive analysis of the possible association between non-syndromic pheochromocytomas and paragangliomas (PPGLs) and other malignancies. To assess >the risk of additional malignancy in PPGL, we retrospectively evaluated 741 patients with PPGLs followed-up in twelve referral centers in Italy. Incidence of second malignant tumors was compared between this cohort and Italian patients with two subsequent malignancies. Among our patients, 95 (12.8%) developed a second malignant tumor, which were mainly prostate, colorectal and lung/bronchial cancers in males, breast cancer, differentiated thyroid cancer and melanoma in females. The standardized incidence ratio was 9.59 (95% CI 5.46–15.71) in males and 13.21 (95% CI 7.52–21.63) in females. At multivariable analysis, the risk of developing a second malignant tumor increased with age at diagnosis (HR 2.50, 95% CI 1.15–5.44, p = 0.021 for 50–59 vs. <50-year category; HR 3.46, 95% CI 1.67–7.15, p < 0.001 for >60- vs. <50-year). In patients with available genetic evaluation, a positive genetic test was inversely associated with the risk of developing a second tumor (HR 0.25, 95% CI 0.10–0.63, p = 0.003). In conclusion, PPGLs patients have higher incidence of additional malignant tumors compared to the general population who had a first malignancy, which could have an impact on the surveillance strategy.